303 related articles for article (PubMed ID: 33606996)
1. Interferon-γ induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation.
Yu M; Peng Z; Qin M; Liu Y; Wang J; Zhang C; Lin J; Dong T; Wang L; Li S; Yang Y; Xu S; Guo W; Zhang X; Shi M; Peng H; Luo X; Zhang H; Zhang L; Li Y; Yang XP; Sun S
Mol Cell; 2021 Mar; 81(6):1216-1230.e9. PubMed ID: 33606996
[TBL] [Abstract][Full Text] [Related]
2. Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models.
Waaler J; Mygland L; Tveita A; Strand MF; Solberg NT; Olsen PA; Aizenshtadt A; Fauskanger M; Lund K; Brinch SA; Lycke M; Dybing E; Nygaard V; Bøe SL; Heintz KM; Hovig E; Hammarström C; Corthay A; Krauss S
Commun Biol; 2020 Apr; 3(1):196. PubMed ID: 32332858
[TBL] [Abstract][Full Text] [Related]
3. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
[TBL] [Abstract][Full Text] [Related]
4. CNOT4 enhances the efficacy of anti-PD-1 immunotherapy in a model of non-small cell lung cancer.
Zhang B; Han S; Ma H; Chen S
FEBS Open Bio; 2020 Dec; 10(12):2631-2639. PubMed ID: 33034149
[TBL] [Abstract][Full Text] [Related]
5. Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells.
Lai Q; Wang H; Li A; Xu Y; Tang L; Chen Q; Zhang C; Gao Y; Song J; Du Z
Oncogene; 2018 Apr; 37(17):2302-2312. PubMed ID: 29422611
[TBL] [Abstract][Full Text] [Related]
6. Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.
Pai CS; Huang JT; Lu X; Simons DM; Park C; Chang A; Tamaki W; Liu E; Roybal KT; Seagal J; Chen M; Hagihara K; Wei XX; DuPage M; Kwek SS; Oh DY; Daud A; Tsai KK; Wu C; Zhang L; Fasso M; Sachidanandam R; Jayaprakash A; Lin I; Casbon AJ; Kinsbury GA; Fong L
Immunity; 2019 Feb; 50(2):477-492.e8. PubMed ID: 30737146
[TBL] [Abstract][Full Text] [Related]
7. m
Wang L; Hui H; Agrawal K; Kang Y; Li N; Tang R; Yuan J; Rana TM
EMBO J; 2020 Oct; 39(20):e104514. PubMed ID: 32964498
[TBL] [Abstract][Full Text] [Related]
8. Abrogation of IFN-γ Signaling May not Worsen Sensitivity to PD-1/PD-L1 Blockade.
Vackova J; Piatakova A; Polakova I; Smahel M
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32155707
[TBL] [Abstract][Full Text] [Related]
9. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the transcriptomic features of microsatellite instability subtype colon cancer.
Wang H; Wang X; Xu L; Zhang J; Cao H
BMC Cancer; 2019 Jun; 19(1):605. PubMed ID: 31221124
[TBL] [Abstract][Full Text] [Related]
11. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
[TBL] [Abstract][Full Text] [Related]
12. YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity.
Ni X; Tao J; Barbi J; Chen Q; Park BV; Li Z; Zhang N; Lebid A; Ramaswamy A; Wei P; Zheng Y; Zhang X; Wu X; Vignali P; Yang CP; Li H; Pardoll D; Lu L; Pan D; Pan F
Cancer Discov; 2018 Aug; 8(8):1026-1043. PubMed ID: 29907586
[TBL] [Abstract][Full Text] [Related]
13. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
[TBL] [Abstract][Full Text] [Related]
14. Multiple roles and context-specific mechanisms underlying YAP and TAZ-mediated resistance to anti-cancer therapy.
Reggiani F; Gobbi G; Ciarrocchi A; Ambrosetti DC; Sancisi V
Biochim Biophys Acta Rev Cancer; 2020 Jan; 1873(1):188341. PubMed ID: 31931113
[TBL] [Abstract][Full Text] [Related]
15. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.
Hsu PC; Miao J; Wang YC; Zhang WQ; Yang YL; Wang CW; Yang CT; Huang Z; You J; Xu Z; Jablons DM; You L
J Cell Mol Med; 2018 Jun; 22(6):3139-3148. PubMed ID: 29575535
[TBL] [Abstract][Full Text] [Related]
17. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Jablons DM; Yang CT; You L
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
[TBL] [Abstract][Full Text] [Related]
18. Loss of VGLL4 suppresses tumor PD-L1 expression and immune evasion.
Wu A; Wu Q; Deng Y; Liu Y; Lu J; Liu L; Li X; Liao C; Zhao B; Song H
EMBO J; 2019 Jan; 38(1):. PubMed ID: 30396996
[TBL] [Abstract][Full Text] [Related]
19. A kinome-wide screen using a NanoLuc LATS luminescent biosensor identifies ALK as a novel regulator of the Hippo pathway in tumorigenesis and immune evasion.
Nouri K; Azad T; Lightbody E; Khanal P; Nicol CJ; Yang X
FASEB J; 2019 Nov; 33(11):12487-12499. PubMed ID: 31431076
[TBL] [Abstract][Full Text] [Related]
20. Increased TEAD4 expression and nuclear localization in colorectal cancer promote epithelial-mesenchymal transition and metastasis in a YAP-independent manner.
Liu Y; Wang G; Yang Y; Mei Z; Liang Z; Cui A; Wu T; Liu CY; Cui L
Oncogene; 2016 May; 35(21):2789-800. PubMed ID: 26387538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
